Compliance Rate
Compliance Rate
100.0%
Compliant submissions
3
Incompliant submissions
0
Total trials
3
My Organizations' Clinical Trials
Showing 55 of 55 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/01/22
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 02/28/14
Due: 02/28/15
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 07/31/16
Due: 07/31/17
Phase: N/A
Priority: Normal
Start: 08/31/14
End: 03/01/22
Due: 03/01/23
Phase: N/A
Priority: Normal
Start: 08/31/04
End: 08/31/06
Due: 08/31/07
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS) | NCT05312177 | Carelon Research | user2@example.com | None | 2022-05-01 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure | NCT01910389 | Carelon Research | user2@example.com | None | 2013-11-30 | 2014-02-28 | 2015-02-28 | - | - | 2025-07-14 |
| Schizophrenia Cognition Scale Development | NCT02118571 | Carelon Research | user2@example.com | None | 2013-11-30 | 2016-07-31 | 2017-07-31 | - | - | 2025-07-14 |
| Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia | NCT02060630 | Carelon Research | user2@example.com | None | 2014-08-31 | 2022-03-01 | 2023-03-01 | - | - | 2025-07-14 |
| Behavior Enhances Drug Reduction of Incontinence (BE-DRI) | NCT00090584 | Carelon Research | user2@example.com | None | 2004-08-31 | 2006-08-31 | 2007-08-31 | - | - | 2025-07-14 |